417 related articles for article (PubMed ID: 28073003)
1. Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
Halbrook CJ; Lyssiotis CA
Cancer Cell; 2017 Jan; 31(1):5-19. PubMed ID: 28073003
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer cell metabolism in pancreatic adenocarcinoma.
Cohen R; Neuzillet C; Tijeras-Raballand A; Faivre S; de Gramont A; Raymond E
Oncotarget; 2015 Jul; 6(19):16832-47. PubMed ID: 26164081
[TBL] [Abstract][Full Text] [Related]
3. Lower maximum standardized uptake value of fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography imaging in pancreatic ductal adenocarcinoma patients with diabetes.
Chung KH; Park JK; Lee SH; Hwang DW; Cho JY; Yoon YS; Han HS; Hwang JH
Am J Surg; 2015 Apr; 209(4):709-16. PubMed ID: 25616974
[TBL] [Abstract][Full Text] [Related]
4. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
Kim YI; Kim SK; Paeng JC; Lee HY
Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
[TBL] [Abstract][Full Text] [Related]
5. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma.
Yamamoto K; Brender JR; Seki T; Kishimoto S; Oshima N; Choudhuri R; Adler SS; Jagoda EM; Saito K; Devasahayam N; Choyke PL; Mitchell JB; Krishna MC
Cancer Res; 2020 Jun; 80(11):2087-2093. PubMed ID: 32245793
[TBL] [Abstract][Full Text] [Related]
7. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways.
Guillaumond F; Iovanna JL; Vasseur S
Arch Biochem Biophys; 2014 Mar; 545():69-73. PubMed ID: 24393743
[TBL] [Abstract][Full Text] [Related]
9. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
Tuerhong A; Xu J; Shi S; Tan Z; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Liang C
Cell Mol Life Sci; 2021 Jul; 78(14):5505-5526. PubMed ID: 34131808
[TBL] [Abstract][Full Text] [Related]
10. Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze.
Olivares O; Vasseur S
Int J Cancer; 2016 Feb; 138(4):787-96. PubMed ID: 25732227
[TBL] [Abstract][Full Text] [Related]
11. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
[TBL] [Abstract][Full Text] [Related]
12. Screening for early pancreatic ductal adenocarcinoma: an urgent call!
Lee MX; Saif MW
JOP; 2009 Mar; 10(2):104-8. PubMed ID: 19287101
[TBL] [Abstract][Full Text] [Related]
13. The 'SPARC' of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review).
Rossi MK; Gnanamony M; Gondi CS
Int J Oncol; 2016 May; 48(5):1765-71. PubMed ID: 26983777
[TBL] [Abstract][Full Text] [Related]
14. Exploiting pancreatic cancer metabolism: challenges and opportunities.
De Santis MC; Bockorny B; Hirsch E; Cappello P; Martini M
Trends Mol Med; 2024 Jun; 30(6):592-604. PubMed ID: 38604929
[TBL] [Abstract][Full Text] [Related]
15. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1: a marker for pancreatic cancer diagnosis.
Tanase CP
Expert Rev Mol Diagn; 2008 Jul; 8(4):395-404. PubMed ID: 18598222
[TBL] [Abstract][Full Text] [Related]
17. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Biochim Biophys Acta; 2016 Dec; 1866(2):177-188. PubMed ID: 27600832
[TBL] [Abstract][Full Text] [Related]
18. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC.
Xiang J; Liu L; Wang W; Xu H; Wu C; Xu J; Liu C; Long J; Ni Q; Yu X
Cancer Lett; 2015 Apr; 359(2):165-8. PubMed ID: 25617800
[TBL] [Abstract][Full Text] [Related]
19. Targeting pancreatic ductal adenocarcinoma acidic microenvironment.
Cruz-Monserrate Z; Roland CL; Deng D; Arumugam T; Moshnikova A; Andreev OA; Reshetnyak YK; Logsdon CD
Sci Rep; 2014 Mar; 4():4410. PubMed ID: 24642931
[TBL] [Abstract][Full Text] [Related]
20. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
